Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nuvamid SA currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. This volume of pending work indicates an active period of patent prosecution for the company. The 4 actions represent multiple opportunities for the company to secure patent rights for its pharmaceutical and biotechnological developments.
The prosecution is handled by 4 distinct examiners across 2 distinct art units. This structure shows that while the company is dealing with 4 different individuals, the technical focus is concentrated within just 2 art units. This concentration suggests that the 4 pending office actions likely relate to two main technical themes. Practitioners can benefit from this by identifying commonalities in how these 2 art units handle similar subject matter, even though 4 different examiners are involved.
MCINTOSH III, TRAVISS C is the busiest examiner for Nuvamid SA, with 1 pending office action. Because each of the 4 pending office actions is assigned to a different examiner, the workload is evenly distributed across the examination team. MCINTOSH III, TRAVISS C is one of the 4 distinct examiners contributing to the current prosecution cycle. The company's success will depend on successfully navigating the individual requirements of each of these 4 examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCINTOSH III, TRAVISS C | 1 | 73.3% | +14.1% |
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| BRANDSEN, BENJAMIN MICHAEL | 1 | 60.9% | +21.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570879 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | KRISHNAN, GANAPATHY | — |
| 17919559 | NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS | HAVLIN, ROBERT H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18817541 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | MCINTOSH III, TRAVISS C | — |
| 17919559 | NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS | HAVLIN, ROBERT H | — |
| 17785631 | NOVEL NICOTINAMIDE DI-NUCLEOTIDE DERIVATIVES AND USE THEREOF | BRANDSEN, BENJAMIN MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1693 | 3 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18817541 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | MCINTOSH III, TRAVISS C | 1693 | §103 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18570879 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | KRISHNAN, GANAPATHY | 1693 | §103§112 | Final Rejection | — | Pending | Dec 15, 2023 |
| 17919559 | NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS | HAVLIN, ROBERT H | 1626 | §102§103Other | Non-Final OA | — | Pending | Oct 18, 2022 |
| 17785631 | NOVEL NICOTINAMIDE DI-NUCLEOTIDE DERIVATIVES AND USE THEREOF | BRANDSEN, BENJAMIN MICHAEL | 1693 | §112Other | Non-Final OA | — | Pending | Jun 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNuvamid SA has 4 pending office actions as of October 2026, spread across 2 art units and 4 examiners.
Traviss C Mcintosh III has the most, with 1 of Nuvamid SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
